UFHCC is going to the American Society of Hematology (ASH) Annual Meeting that will be held at the Orange County Convention Center in Orlando on Dec. 7-10, 2019.

ASH is the most comprehensive hematology event of the year. The meeting will provide an invaluable educational experience and overview of the latest scientific highlights in hematology. ASH is a great opportunity for hematology/oncology researchers to engage with your colleagues and network with more than 25,000 hematology professionals from every sub-specialty.

UFHCC will be represented by 18 posters and nine oral research presentations featuring our research as well as three special interest sessions. Come say hello to your colleagues, check out our abstracts and stop by our booth.

The full conference program is available here.

Dec. 7

Hottip Lncrna Reinforces CTCF Defined Chromatin Boundaries and Drives Wnt Target Gene Expression in AML Leukemogenesis

Presenter: Huacheng Luo

Authors Include: Yi Qiu

Sunburst Room (W340)

4 – 5:30 p.m.

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

Presenter: Ryosuke Shirasaki

Authors Include: Jonathan D. Licht

Hall E2

4 – 5:30 p.m.

Outcome in Adolescent and Young Adult (AYA) Patients Compared to Younger Patients Treated for High-Risk B-Lymphoblastic Leukemia (HR B-ALL): Report from the Children’s Oncology Group Study AALL0232

Presenter: Michael Burke

Authors Include: Zhiguo Chen*

W224

4 – 5:30 p.m.

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

Presenter: Yonghan He

Authors Include: Yonghan He*, Vivekananda Budamagunta*, Dongwen Lv*, Sajid Khan*, Xuan Zhang*, Janet S Wiegand, Guangrong Zheng and Daohong Zhou

Valencia A (W415A)

4 – 5:30 p.m.

Dec. 9

DNMT3A with Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks

Presenter: Kartika Venugopal

Authors Include: Kartika Venugopal*, Daniil E Shabashvili*, Jianping Li*, Luisa M Posada*, Richard Lynn Bennett, Yang Feng*, Daphne Dupere Richer*, Alberto Riva*, Santhi Pondugula*, Jonathan E. Bird*, Jonathan D. Licht and Olga A Guryanova

W307, Level 3

7 a.m.

The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia

Presenter: Kathryn Roberts

Authors Include: Yunfeng Dai*

W224ABEF

10:30 – 12 a.m.

FoxM1 Haploinsufficiency Drives Clonal Hematopoiesis

Presenter: Chunjie Yu

Authors Include: Chunjie Yu*, Yue Sheng* and Zhijian Qian

Valencia D (W415D)

2:45 – 4:15 p.m.

Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children’s Oncology Group (COG) Study AALL0932

Presenter: Anne Angiolillo

Authors Include: John Kairalla and Cindy Wang*

Tangerine 1 (WF1)

4:30 – 6 p.m.

Novel CD33 Antibodies Unravel Localization, Biology, and Therapeutic Implications of CD33 Isoforms

Presenter: Mohammed Gbadamosi

Authors Include: Mohammed Gbadamosi* and Jatinder K Lamba

W308

6:15 – 7:45 p.m.

Dec. 7

Long-Term Clearance of Senescent Cells Prevents the Hematopoietic Stem Cell Aging in Naturally Aged Mice

Presenter: Yonghan He

Authors Include: Yonghan He*, Dongwen Lv*, Xin Zhang* and Daohong Zhou

Hall B

5:30 – 7:30 p.m.

FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children’s Oncology Group Study

Presenter: Patrick Brown

Authors Include: John Kairalla and Cindy Wang*

Hall B

5:30 – 7:30 p.m.

A 5-Gene Ara-C, Daunorubicin and Etoposide (ADE) Drug Response Score As a Prognostic Tool to Predict AML Treatment Outcome

Presenter: Abdelrahman Elsayed

Authors Include: Abdelrahman H. Elsayed* and Jatinder K Lamba

Hall B

5:30 – 7:30 p.m.

Preliminary Lasso Regression Analysis Identifies DNA-Damage Gene Expression Signature Predictive of Clinical Outcomes in Patients Using Gemtuzumab Ozogamicin

Presenter: Mohammed Gbadamosi

Authors Include: Mohammed Gbadamosi*, Abdelrahman H. Elsayed* and Jatinder K Lamba

Hall B

5:30 – 7:30 p.m.

CRISPR Dropout Screens Identify DHODH, PIK3C3, and Crkl as Potential Therapeutic Targets in Acute Myeloid Leukemia

Presenter: Gregory Takacs

Authors Include: Gregory Takacs*, Yujia Zhou*, David J. King*, Amy Meacham*, Loguinov Alex*, Abderrahmane Tagmount*, Amin Sobh*, Max Russo*, Chris D Vulpe and Christopher R. Cogle

Hall B

5:30 – 7:30 p.m.

Lower Hematopoietic Progenitor Cell Counts and Yields at Subsequent Donations Is Influenced By a Shorter Inter-Donation Interval between the First and Subsequent Mobilizations

Presenter: Sandhya Panch

Authors Include: Jack W. Hsu

Hall B

5:30 – 7:30 p.m.

Dec. 8

Impact of Renal Dysfunction Measured By Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT)

Presenter: Ajoy Dias

Authors Include: Nosha Farhadfar and John R. Wingard

Hall B

6 – 8 p.m.

The Innate Immune Sensor Sting Promotes Donor CD8+ T Cell Activation and Recipient APC Death Early after Preclinical Allogeneic Hematopoietic Stem Cell Transplantation

Presenter: Cameron Bader

Authors Include: Lei Jin

Hall B

6 – 8 p.m.

Residual TP53 Mutation Contributes to Chemoresistance through Clonal Expansion in Acute Myeloid Leukemia

Presenter: Bowen Yan

Authors Include: Bowen Yan*, Qinwei Chen* and Yi Qiu 

Hall B

6 – 8 p.m.

Genome-Scale CRISPR-Cas9 Synthetic Lethal Screening of AML Cell Line Identified Functional Modulators of Etoposide Resistance Predictive of Clinical Outcome in AML Patients

Presenter: Roya Rafiee

Authors Include: Roya Rafiee*, Amin Sobh*, Abdelrahman H. Elsayed*, Abderrahmane Tagmount*, Chris D Vulpe and Jatinder K Lamba

Hall B

6 – 8 p.m.

Dec. 9

Identification of Genetic Vulnerabilities and Synthetic-Lethal Targets in NSD2-High Multiple Myeloma

Presenter: Amin Sobh

Authors Include: Amin Sobh*, Charlotte Kaestner*, Alberto Riva* and Jonathan D. Licht

Hall B, Level 2

6 – 8 p.m.

A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance Via Blocking Receptor Auto-Induction and BIM/Bmf Expression in ALL

Presenter: Jianping Li

Authors Include: Jianping Li*, Catalina Troche*, Alok Swaroop*, Marta Kulis*, Daphne Dupere-Richer*, Alberto Riva*, Amin Sobn*, Sharon Norton*, Richard Lynn Bennett and Jonathan D. Licht

Hall B

6 – 8 p.m.

Tumor Suppressor Function of Dnmt3b in Hematologic Malignancies Critically Depends on Its Catalytic Activity

Presenter: Rene Opavsky

Authors Include: Katarina Lopusna*, Pawel Nowialis*, Ajay Abraham*, Jana Opavska* and Rene Opavsky

Hall B

6 – 8 p.m.

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Presenter: Qi Zhang

Authors Include: Sajid Khan*, Xuan Zhang*, Guangrong Zheng and Daohong Zhou

Hall B

6 – 8 p.m.

Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias – Implications for the Biology and Therapeutic Targeting of Myeloma

Presenter: Ricardo De Matos Simoes

Authors Include: Jonathan D. Licht

Hall B

6 – 8 p.m.

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Presenter: Polina Shindiapina

Authors Include: Jack W. Hsu

Hall B

6 – 8 p.m.

Diet Quality of Long-Term Allogeneic and Autologous Stem Cell Transplant (HCT) Survivors

Presenter: Nosha Farhadfar

Authors Include: Nosha Farhadfar, Debra Lynch Kelly, Lacey E. Mead*, Shalini Nair*, Randy A. Brown, John W. Hiemenz, Jack W. Hsu, W. Stratford May, John R. Wingard and Wendy J Dahl*

Hall B

6 – 8 p.m.

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect® MDS/AML Registry

Presenter: Tracy George

Authors Include: Christopher R. Cogle

Hall B

6 – 8 p.m.